Analyst Rating Update on Geron Corporation (GERN)

Geron Corporation (NASDAQ:GERN) has an average broker rating of 1.5, which is interpreted as a Strong Buy, as rated by 4 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Geron Corporation (NASDAQ:GERN) : 3 investment research analysts covering Geron Corporation (NASDAQ:GERN) have an average price target of $7.5 for the near short term. The highest target price given by the Brokerage Firm to the stock is $10 and the lowest target is $6 for the short term. Analysts expect the variance to be within $2.18 of the average price.

For the current week, the company shares have a recommendation consensus of Buy.

Geron Corporation (NASDAQ:GERN): stock turned positive on Tuesday. Though the stock opened at $2.49, the bulls momentum made the stock top out at $2.65 level for the day. The stock recorded a low of $2.484 and closed the trading day at $2.64, in the green by 9.09%. The total traded volume for the day was 2,594,095. The stock had closed at $2.42 in the previous days trading.

In an insider trading activity, The officer (EVP, Chief Financial Officer), of Geron Corp, Bloom Olivia Kyusuk had unloaded 2,380 shares at $3.84 per share in a transaction on May 29, 2015. The total value of transaction was $9,139. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.